CDK9-IN-25
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM) . CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM) [1].
Product Specifications
UNSPSC
12352005
Target
CDK; SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/cdk9-in-25.html
Solubility
10 mM in DMSO
Smiles
CC(C)(C)NC1=C(N=C2N1C=CN=C2)C3=CC(F)=NC=C3
Molecular Formula
C15H16FN5
Molecular Weight
285.32
References & Citations
[1]Alsfouk AA, et al. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel) . 2023 Jul 18;16 (7) :1018..
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682007-500 1x 500 µL
MHC II, Mouse (MK-D6), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNUB3015-100 1x 100 µL
MerTK (Innate Immune Checkpoint) (MERTK/3015), 0.2mg/mL
Sign In for Pricing
View Details